
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is a financially stable healthcare company with diverse revenue streams and a strong focus on antibiotic stewardship. Their patented products have shown promising results in critical care and infectious disease, and their recent acquisition of an extended release platform for oral small molecules positions them for continued success in the future. With the potential for new treatments and a focus on increasing the use of their existing products, Innoviva is a strong investment opportunity in the healthcare industry.
Bears say
Innoviva is placing a heavy emphasis on its partnership with Armata and its potential for success in Phase 3 trials which is not projected to occur until 2026, indicating a long-term outlook. Additionally, the company's current product offerings and strategic assets have not been able to generate significant revenue or profits, potentially hindering future growth. The economic burden and challenges of treating antibiotic-resistant infections also pose long-term risks for the company if its products are not successful in addressing this issue.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares